5MC Stock Overview A biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Leap Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Leap Therapeutics Historical stock prices Current Share Price US$3.16 52 Week High US$4.54 52 Week Low US$1.48 Beta 0.17 1 Month Change 13.67% 3 Month Change 51.92% 1 Year Change -13.19% 3 Year Change -87.51% 5 Year Change -80.61% Change since IPO -95.22%
Recent News & Updates
Leap Therapeutics, Inc. Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients Oct 01
Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024 May 01 Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP Apr 12
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium Jan 17
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients Jan 02
Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients Jul 13 See more updates
Leap Therapeutics, Inc. Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients Oct 01
Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024 May 01 Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP Apr 12
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium Jan 17
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients Jan 02
Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients Jul 13
Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share Requirements Jun 21
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting May 26
Leap Therapeutics, Inc. (NasdaqGM:LPTX) acquired Flame Biosciences, Inc from Acuta Capital Partners LLC, Adage Capital Management, L.P., Cormorant Asset Management, LP, Cormorant Asset Management, LP, Terra Magnum Capital Partners and others. Jan 19
Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors Jan 18
Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021) Nov 16 Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
Leap Therapeutics, Inc. Announces First Patient Enrolled in Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients Oct 18
Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 Distinguish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer Oct 13
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting Oct 06
Leap Therapeutics, Inc. Announces Appointment of Richard L. Schilsky, MD to its Board of Directors Sep 07
Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq at the ESMO Congress Sep 05
First half 2022 earnings released Aug 13
Leap Therapeutics, Inc. Resigns Dr. Monica Bertagnolli, as Director Aug 13
Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer Jul 13
Leap Therapeutics, Inc. to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting May 27
First quarter 2022 earnings released: US$0.092 loss per share (vs US$0.12 loss in 1Q 2021) May 14
Insufficient new directors Apr 27
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 12
Leap Therapeutics to Present Positive New Data from the Distinguish Study of DKN-01 Plus Tislelizumab at the Asco GI Cancers Symposium Jan 19
Insufficient new directors Jan 02
Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.092 loss in 3Q 2020) Nov 13
Leap Therapeutics to Present New Data from the Distinguish Study of Dkn-01 Plus Tislelizumab At the Esmo 2021 Congress Sep 14
First half 2021 earnings released: US$0.24 loss per share (vs US$0.57 loss in 1H 2020) Aug 18
First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.55 loss in 1Q 2020) May 16
Leap Therapeutics, Inc. Provides DKN-01 Development Update Mar 14
Revenue misses expectations Mar 13
New 90-day high: €2.18 Feb 09
New 90-day high: €2.00 Jan 20
New 90-day low: €1.27 Nov 11
Leap Therapeutics, Inc. Announces the Presentation of Clinical Data from Its Phase 1b/2a Clinical Trial of DKN-01 in Patients with Advanced Esophagogastric Cancer Nov 10
New 90-day high: €1.84 Oct 19 Leap Therapeutics, Inc. announced that it has received $26.985796 million in funding from Perceptive Advisors LLC, BeiGene, Ltd., Baker Bros. Advisors LP
Leap Therapeutics, Inc. Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer Sep 26
Leap Therapeutics and Beigene Announces First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer Sep 22
New 90-day low - €1.50 Aug 25
New 90-day low - €1.52 Jul 21
Leap Therapeutics, Inc.(NasdaqGM:LPTX) dropped from Russell Microcap Value Index Jul 03 Shareholder Returns 5MC DE Biotechs DE Market 7D 16.2% 1.9% 1.4% 1Y -13.2% -9.8% 9.1%
See full shareholder returns
Return vs Market: 5MC underperformed the German Market which returned 7.4% over the past year.
Price Volatility Is 5MC's price volatile compared to industry and market? 5MC volatility 5MC Average Weekly Movement 15.7% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 5MC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5MC's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd.
Show more Leap Therapeutics, Inc. Fundamentals Summary How do Leap Therapeutics's earnings and revenue compare to its market cap? 5MC fundamental statistics Market cap €123.58m Earnings (TTM ) -€62.41m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 5MC income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$64.82m Earnings -US$64.82m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/06 15:39 End of Day Share Price 2025/01/06 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Leap Therapeutics, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Madhu Kumar Baird Joel Beatty Baird Swayampakula Ramakanth H.C. Wainwright & Co.
Show 3 more analysts 
